

U.S. Serial No. 10/595,892

Attorney Docket No. PR60416USw

REMARKS

In response to the restriction/lack of unity requirement, Applicant elects without traverse Group I, claims 1-25 and 27, drawn to compounds and pharmaceutical compositions comprising compounds of formula (I) wherein A=OH. A compound in which A=OH is, for example, Examples 25 and 26 in the specification, particularly Example 26: (+)-(Trans)-2-{4-[(3-phenoxybenzyl)amino]phenyl}cyclopropanecarboxylic acid; see also Claim 25, page 7 of preliminary amendment, lines 21-23, or in the published specification (WO2005/051890) at page 81, lines 7-9. Claims readable on the elected species are Claims 1-25 and 27.

Respectfully submitted:

Bonnie L. Deppenbrock

Bonnie L. Deppenbrock
Attorney for Applicant
Reg. No. 28,209

Date: October 5, 2009
GlaxoSmithKline Inc.
Corporate Intellectual Property
Five Moore Drive, P.O. Box 13398
Research Triangle Park, NC 27709
Tel. (919) 483-1577
Fax: (919) 483-7988